RT induces upregulation of OX40 expression on CD4+ and CD8+ T cells as well as CD137 on CD8+ tumor infiltrating T cells and thus works in concert with agonistic OX40 or CD137 therapy (66–68). The gene discussed is CD8A; the disease is neoplasm.